Compare

Sana Biotechnology/$SANA

1D1W1M3M6MYTD1Y5YMAX

About Sana Biotechnology

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Ticker
$SANA
Sector
Health
Primary listing
NASDAQ
Employees
142
Headquarters
Seattle, United States
Website
www.sana.com

SANA Metrics

BasicAdvanced
$766M
-
-$0.76
2.13
-

What the Analysts think about SANA

Analyst ratings (Buy, Hold, Sell) for Sana Biotechnology stock.
Analyst projections of the future price of Sana Biotechnology stock.

Bulls say / Bears say

UP421’s transplanted islet cells were still producing insulin-related C-peptide after 14 months, with no safety issues reported and no immunosuppression. This is early human evidence that Sana’s hypoimmune approach may help transplanted cells evade immune rejection. (Sana Biotechnology)
Sana is preparing SC451, a stem-cell-derived islet therapy for type 1 diabetes, for an IND and Phase 1/2 trial, and Mayo Clinic invested $25 million as part of a collaboration to support its development. If the approach works, the company is aiming for a one-time treatment without insulin or immunosuppressive drugs. (Sana Biotechnology)
In non-human primates, a surrogate for SG293 showed targeted delivery and deep B-cell depletion without chemotherapy to prepare the immune system. Sana sees scope to test this in vivo CAR T approach in lymphoma and, if successful, autoimmune disease. (Sana Biotechnology)
The UP421 result comes from a low-dose study in one patient and was not designed to show better blood-sugar control or reduced insulin use. It therefore does not yet prove that Sana’s stem-cell-derived SC451 can deliver a functional treatment at scale. (Sana Biotechnology)
Sana had $160.5 million in cash and marketable securities at June 2026, but its filing said it may not have enough resources to fund planned operations for a year and disclosed substantial doubt about its ability to continue as a going concern. Further funding may be needed, with potential dilution for shareholders. (SEC)
The lead programmes still face clinical and regulatory hurdles: in September, management expected SG293’s first human data in the first half of 2027, while SC451 was still being prepared for an IND and trial start. Delays or weak early results could postpone evidence that either platform works in patients. (Investing.com, Sana Biotechnology)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2026.

SANA Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

SANA Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing SANA

Funds
Fund name
Fund size
$SANA weighting
iShares Nasdaq US Biotechnology£BTEK
$1.1B0.05%
iShares Nasdaq US Biotechnology$BTEC
$1.1B0.05%
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.02%
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.02%
Xtrackers MSCI World Small Cap$XSWC
$183M0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.